Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Income from Continuing Operations (2016 - 2025)

KalVista Pharmaceuticals' Income from Continuing Operations history spans 11 years, with the latest figure at 52190000.0 for Q2 2025.

  • For Q2 2025, Income from Continuing Operations fell 11.18% year-over-year to 52190000.0; the TTM value through Apr 2025 reached 184028000.0, down 38.25%, while the annual FY2025 figure was 95044000.0, 24.95% up from the prior year.
  • Income from Continuing Operations for Q2 2025 was 52190000.0 at KalVista Pharmaceuticals, down from 44453000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12520000.0 in Q1 2021 and bottomed at 52190000.0 in Q2 2025.
  • The 4-year median for Income from Continuing Operations is 34735500.0 (2024), against an average of 35339500.0.
  • The largest annual shift saw Income from Continuing Operations decreased 1.36% in 2021 before it plummeted 53.44% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 12520000.0 in 2021, then tumbled by 131.39% to 28970000.0 in 2023, then tumbled by 53.44% to 44453000.0 in 2024, then dropped by 17.4% to 52190000.0 in 2025.
  • Per Business Quant, the three most recent readings for KALV's Income from Continuing Operations are 52190000.0 (Q2 2025), 44453000.0 (Q4 2024), and 40443000.0 (Q3 2024).